AstraZeneca PLC
AZNHealthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +23.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
Follow AZN
Alert me
AstraZeneca PLC (AZN) P/E ratio
As of Nov 19, 2026, AstraZeneca PLC (AZN) trades at a P/E ratio of 24.6×. Over the past ten years it has ranged from 0.0× (September 2022) to 454× (March 2022); the current reading is higher than 14% of that period. That is in line with the Drug Manufacturers General industry median of 25.3× and above the Healthcare sector median of 22.4×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 26.6× | (7.01%) |
| FY2024 | 28.6× | (16.91%) |
| FY2023 | 34.4× | (46.03%) |
| FY2022 | 63.8× | (83.49%) |
| FY2021 | 386× | 840.56% |
| FY2020 | 41.1× | (56.91%) |
| FY2019 | 95.3× | 113.25% |
| FY2018 | 44.7× | 55.04% |
| FY2017 | 28.8× | 44.56% |
| FY2016 | 19.9× | (33.65%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 22.7× | (19.39%) |
| Jun 2026 | 28.1× | (4.28%) |
| Mar 2026 | 29.4× | 10.53% |
| Dec 2025 | 26.6× | 7.89% |
| 43 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GILD Gilead Sciences, Inc. compare | n/m |
| NVO Novo Nordisk A/S compare | 9.8× |
| BMY Bristol Myers Squibb Company compare | 12.9× |
| AZN AstraZeneca PLC | 24.6× |
| AMGN Amgen Inc. compare | 25.2× |
| NVS Novartis AG compare | 28.8× |
| PFE Pfizer Inc. compare | 38.8× |
| ABBV AbbVie Inc. compare | 48.8× |
| MRK Merck & Co., Inc. compare | 137× |
| Drug Manufacturers General industry median | 25.3× |
| Healthcare sector median | 22.4× |
| Market median | 16.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on AZN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement